DISEASE CHARACTERISTICS:

• Idiopathic myelofibrosis (IMF) with at least 1 poor prognosis characteristic, including but not limited to:

  • Hemoglobin less than 10 g/dL
  • Platelet count less than 100,000/mm^3
  • Hepatomegaly (i.e., palpable liver edge 5 cm below costal margin)
  • Clinical requirement for splenectomy
• Other myeloproliferative disorders in an IMF like myelofibrotic state eligible

• No evidence of leukemic progression, e.g.:

  • Greater than 15% peripheral blood blasts
  • Fever or bone pain of unknown origin
  • Rapidly progressing splenomegaly

• No other causes for myelofibrosis, such as:

  • Collagen vascular disorder
  • Lymphoma
  • Granulomatous infection
  • Metastatic carcinoma
  • Hairy cell leukemia
  • Myelodysplastic syndrome
• No active central nervous system disease

• One of the following donor/patient pairings is required:

  • Donor status:

    • Genotypic or phenotypic HLA-matched relative

      • Maximum patient age of 65

    • One antigen HLA-mismatched relative, HLA-matched unrelated donor, or one antigen HLA-mismatched unrelated donor

      • Maximum patient age of 55
• Transplant on this protocol allowed for patients registered on protocol FHCRC-1106.00

PATIENT CHARACTERISTICS:

Age:

• 65 and under

Performance status:

• Not specified

Hematopoietic:

• See Disease Characteristics

Hepatic:

• Bilirubin no greater than 2 times normal
• SGPT no greater than 4 times normal

Renal:

• Creatinine no greater than two times normal OR
• Creatinine clearance at least 50%

Cardiovascular:

• Ejection fraction at least 50%
• Cardiac evaluation required if signs or symptoms of coronary artery disease or congestive heart failure

Other:

• HIV negative
• No active infection
• Patients excluded from this protocol are referred to protocol FHCRC-179.05

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Not specified

Chemotherapy:

• Not specified

Endocrine therapy:

• Not specified

Radiotherapy:

• Not specified

Surgery:

• Not specified